Hippocampal avoidance and memantine remain inconsistently offered in surveyed whole-brain RT practices

Only 22.6% of surveyed radiation oncologists routinely offered both hippocampal avoidance and memantine, while 46.8% offered neither as standard options.

KEY POINTS

  • This multinational cross-sectional survey included 124 radiation oncologists from 45 centers across 15 countries in the Middle East and North Africa (MENA). The anonymous questionnaire was distributed through email and professional social media between January and March 2025, without a defined sampling frame or calculable response rate; all findings represent self-reported practices among respondents, not verified center-level performance.
  • Routine offering of hippocampal-avoidance whole-brain radiotherapy (HA-WBRT) to eligible patients was reported by 60/124 clinicians (48.4%), while 34/124 (27.4%) routinely offered memantine. Only 28 respondents (22.6%) reported routinely offering both interventions, whereas 58 (46.8%) offered neither as a standard option.
  • Reported actual utilization was even lower than routine offering. When asked what proportion of their WBRT patients received both HA-WBRT and memantine, 70/124 respondents (56.5%) answered never, while only 4/124 (3.2%) reported using both interventions in more than half of their patients.
  • Availability and clinician familiarity appeared important for memantine adoption. Only 48 respondents (38.7%) reported that memantine was available at their center, while 66 (53.2%) did not know whether it was approved for use in brain metastases. Reported drug availability was strongly associated with routinely offering memantine (OR 6.60, 95% CI 2.76–15.80; p<0.001).
  • The most frequently reported barriers to HA-WBRT were concern about missing intracranial disease (58.1%), resource-intensive treatment planning (53.2%), and potential delays in starting treatment (41.9%). For memantine, the leading barriers were lack of experience with the drug (67.7%), perceived insufficient evidence (47.6%), and reimbursement difficulties (46.8%).
  • Formal cognitive assessment was uncommon: 90/124 respondents (72.6%) reported using no cognitive assessment instrument, while 22 (17.7%) used the Mini-Mental State Examination and 6 (4.8%) used the Hopkins Verbal Learning Test. In addition, 54 respondents (43.5%) reported no routine follow-up after WBRT, limiting opportunities to systematically identify neurocognitive deterioration.
  • The respondent distribution was uneven, with 52 clinicians (41.9%) from Saudi Arabia and 23 (18.5%) from Egypt, and some institutions contributing multiple responses. Reported prescribing practices were also inconsistent across questionnaire items; together with voluntary participation, self-reporting and possible selection bias, these limitations prevent extrapolation of the observed percentages to the wider MENA region.

CLINICAL TAKEAWAY

Hippocampal avoidance and memantine are evidence-supported strategies for reducing cognitive decline in eligible patients receiving whole-brain radiotherapy, yet this survey suggests inconsistent discussion and use among participating clinicians. The findings support greater attention to education, treatment-planning resources, drug availability and standardized cognitive follow-up, but should not be interpreted as representative estimates of regional practice or evidence of individual clinician noncompliance.

SOURCE

Frontiers in Oncology

Browse more research Suggest a correction